Auxilium Pharmaceuticals Company Profile (NASDAQ:AUXL)

About Auxilium Pharmaceuticals (NASDAQ:AUXL)

Auxilium Pharmaceuticals logoAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men's healthcare. The company's products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biopharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:AUXL
  • CUSIP: 05334D10
  • Web:
Average Prices:
  • 50 Day Moving Avg: $37.00
  • 200 Day Moving Avg: $30.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 22.65
  • P/E Growth: 0
  • Dividend Yield: 1.0%
  • Net Margins: -29.78%
  • Return on Equity: -76.75%
  • Return on Assets: -11.59%

Frequently Asked Questions for Auxilium Pharmaceuticals (NASDAQ:AUXL)

What is Auxilium Pharmaceuticals' stock symbol?

Auxilium Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUXL."

How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) announced its quarterly earnings results on Thursday, October, 30th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.03) by $0.30. The business earned $109.60 million during the quarter, compared to analyst estimates of $101.02 million. Auxilium Pharmaceuticals had a negative return on equity of 76.75% and a negative net margin of 29.78%. The firm's revenue was up 1.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.17 EPS. View Auxilium Pharmaceuticals' Earnings History.

Who are some of Auxilium Pharmaceuticals' key competitors?

How do I buy Auxilium Pharmaceuticals stock?

Shares of Auxilium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auxilium Pharmaceuticals' stock price today?

One share of Auxilium Pharmaceuticals stock can currently be purchased for approximately $36.47.

MarketBeat Community Rating for Auxilium Pharmaceuticals (NASDAQ AUXL)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  202 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Auxilium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Auxilium Pharmaceuticals (NASDAQ:AUXL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Auxilium Pharmaceuticals (NASDAQ:AUXL)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016MKM PartnersDowngradeBuy -> Neutral$32.00 -> $33.25N/AView Rating Details
(Data available from 9/19/2015 forward)


Earnings History for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Earnings by Quarter for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Earnings History by Quarter for Auxilium Pharmaceuticals (NASDAQ AUXL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2014Q314($0.03)$0.27$101.02 million$109.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.21)($0.54)$482.80 million$83.00 millionViewListenView Earnings Details
5/5/2014Q114($0.14)($0.39)$89.20 million$8.50 millionViewListenView Earnings Details
2/28/2014Q413$0.22$0.27$111.83 million$125.90 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.03)$0.02$91.43 million$100.50 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.02($0.05)$81.23 million$66.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.72$1.83$171.20 million$172.50 millionViewListenView Earnings Details
11/7/2012Q312($0.07)($0.21)$79.54 million$71.00 millionViewN/AView Earnings Details
7/31/2012($0.05)$0.16ViewN/AView Earnings Details
5/10/2012($0.11)($0.04)ViewN/AView Earnings Details
2/23/2012($0.16)($0.25)ViewN/AView Earnings Details
10/31/2011($0.20)($0.08)ViewN/AView Earnings Details
8/1/2011($0.19)($0.11)ViewN/AView Earnings Details
5/9/2011($0.24)($0.25)ViewN/AView Earnings Details
2/10/2011($0.30)($0.34)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Current Year EPS Consensus Estimate: $-0.13 EPS
Next Year EPS Consensus Estimate: $1.61 EPS


Dividend History for Auxilium Pharmaceuticals (NASDAQ:AUXL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Insider Trades by Quarter for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Insider Trades by Quarter for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/5/2014Adrian AdamsCEOSell40,000$33.97$1,358,800.00View SEC Filing  
12/5/2014Paul A FriedmanDirectorSell29,689$33.73$1,001,409.97View SEC Filing  
12/3/2014Oliver FetzerDirectorSell100,000$34.02$3,402,000.00View SEC Filing  
11/25/2014James Patrick TursiInsiderSell13,713$34.12$467,887.56View SEC Filing  
11/21/2014Andrew I KovenCAOSell139,683$33.43$4,669,602.69View SEC Filing  
11/21/2014James Patrick TursiInsiderSell74,648$33.19$2,477,567.12View SEC Filing  
11/21/2014Jennifer Lou ArmstrongSVPSell75,803$33.50$2,539,400.50View SEC Filing  
3/14/2014Tito Benjamin Del, Jr.EVPSell32,032$29.50$944,944.00View SEC Filing  
3/5/2014Rolf ClassonDirectorSell10,000$31.85$318,500.00View SEC Filing  
12/13/2013Tito Benjamin Del, Jr.EVPSell4,602$20.50$94,341.00View SEC Filing  
12/11/2013James FickenscherCFOSell71,067$20.37$1,447,634.79View SEC Filing  
8/15/2013Oliver FetzerDirectorSell1,900$18.75$35,625.00View SEC Filing  
5/20/2013William MckeeDirectorSell2,000$15.10$30,200.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Auxilium Pharmaceuticals (NASDAQ:AUXL)
Latest Headlines for Auxilium Pharmaceuticals (NASDAQ:AUXL)
DateHeadline logoFinancial Survey: Auxilium Pharmaceuticals (AUXL) versus Alimera Sciences (ALIM) - September 7 at 8:28 PM logoAuxilium Pharmaceuticals (NASDAQ:AUXL) vs. Biogen (BIIB) Head to Head Analysis - July 24 at 8:22 PM logoPozen to redomicile as it agrees to buy Tribute Pharmaceuticals - June 8 at 10:59 AM logoEndo International (ENDP) Earnings Report: Q1 2015 Conference Call Transcript - May 11 at 2:46 PM logoEndo (ENDP) Beats on Q1 Earnings, 2015 Guidance Updated - Tale of the Tape - May 11 at 8:22 AM logo13F Watch: In Defense of Active Share - February 19 at 10:02 AM logoAuxilium Announces Fundamental Change and Make-Whole Fundamental Change Relating to Outstanding Convertible Senior Notes - February 3 at 8:00 AM logoAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Financial Statements a - January 30 at 4:56 PM logoAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materia - January 29 at 4:50 PM logoAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Regulation FD D - January 27 at 1:38 PM logoEndo Prices $1.2B Senior Notes Offering for Auxilium Deal - Analyst Blog - January 22 at 5:10 PM logoAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Other Events - January 21 at 6:01 AM logoOncoMed Starts Expansion Stage Study for Solid Tumor Drug - Analyst Blog - January 16 at 1:50 PM logoAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - December 22 at 11:16 AM logoAUXILIUM PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers - December 19 at 1:12 PM logoEndo bolsters men's healthcare business with Auxilium deal - October 9 at 2:54 PM logoUS STOCKS-Futures turn lower as global growth concerns weigh - October 9 at 8:15 AM logoEndo to buy Auxilium for $2.6 bln, Auxilium drops QLT deal - October 9 at 6:53 AM logoMoody's says may review M&As if new tax rules lead to altered terms - September 23 at 6:34 PM logoAuxilium says Endo offer undervalues company, but open to talks - September 22 at 11:20 AM logoAuxilium Pharma rejects Endo's takeover offer - September 22 at 7:45 AM logoAuxilium says Endo's offer "significantly undervalues" company - September 22 at 7:25 AM logoFDA OKs faster-acting label for ED drug Stendra - September 18 at 12:21 PM logoFDA panel backs limiting use of testosterone replacement drugs - September 17 at 4:58 PM logoWhy Endo Wants to Acquire Auxilium So Much - September 17 at 10:05 AM logoAuxilium Pharma adopts poison pill after Endo's unsolicited bid - September 17 at 7:23 AM logoEndo's $2.2 bln offer could complicate Auxilium Pharma's QLT deal - September 16 at 10:01 PM



Auxilium Pharmaceuticals (AUXL) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff